Market Cap | 10.31M | P/E | - | EPS this Y | 60.50% | Ern Qtrly Grth | - |
Income | -37.03M | Forward P/E | -1.54 | EPS next Y | 36.40% | 50D Avg Chg | -5.00% |
Sales | 443k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | 0.83 | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | 2.00 | Quick Ratio | 3.14 | Shares Outstanding | 852.93K | 52W Low Chg | 62.00% |
Insider Own | 0.79% | ROA | -71.51% | Shares Float | 844.46K | Beta | 1.02 |
Inst Own | 8.78% | ROE | - | Shares Shorted/Prior | 59.36K/16.17K | Price | 0.94 |
Gross Margin | -271.78% | Profit Margin | - | Avg. Volume | 2,961,535 | Target Price | 100.00 |
Oper. Margin | -2,000.92% | Earnings Date | Nov 12 | Volume | 179,408 | Change | -2.49% |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
HC Wainwright & Co. | Buy | May 16, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
HC Wainwright & Co. | Buy | Mar 11, 24 |
JMP Securities | Market Outperform | May 17, 23 |
JMP Securities | Market Outperform | Mar 31, 23 |
HC Wainwright & Co. | Buy | Mar 31, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Shin Barry | SVP, CFO SVP, CFO | Jun 28 | Sell | 0.41 | 31,785 | 13,032 | 873,056 | 06/29/22 |